BusinessSelecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate UpdateBy Nasdaq OMXNov 7, 2017, 12:30 PM UTC
BusinessHorizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled GoutBy Nasdaq OMXNov 6, 2017, 5:00 PM UTC
BusinessHorizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017By Nasdaq OMXNov 3, 2017, 3:00 PM UTC
BusinessHorizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual MeetingBy Nasdaq OMXOct 23, 2017, 12:01 PM UTC
BusinessSelecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe GoutBy Nasdaq OMXJun 15, 2017, 11:30 AM UTC
BusinessHorizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled GoutBy Nasdaq OMXJun 14, 2017, 1:05 PM UTC
BusinessEpidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993By Nasdaq OMXJun 14, 2017, 1:00 PM UTC
BusinessCymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for ArhalofenateBy Nasdaq OMXJan 20, 2016, 1:00 PM UTC
